Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:22:59 EDT Sat 27 Jul 2024
Enter Symbol
or Name
USA
CA



Q:RNAZ - TRANSCODE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RNAZ - Q6.00.335·0.388510.00.2956-0.0061-2.07,610.42,3963,3710.3068  0.3068  0.2945128.00  0.29419:59:58Jul 2415 min RT 2¢

Recent Trades - Last 10 of 3371
Time ETExPriceChangeVolume
19:59:58Q0.3420.04035,000
19:59:53Q0.3420.040350
19:59:53Q0.3420.0403200
19:59:44Q0.3550.0533300
19:59:42Q0.35990.0582400
19:59:42Q0.35990.0582893
19:59:42Q0.360.0583207
19:59:41Q0.35850.0568100
19:59:37Q0.3570.05531,100
19:59:37Q0.35850.0568250

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-24 16:05U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Closing of Public Offering
2024-07-22 22:30U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Pricing of Public Offering
2024-07-22 16:07U:RNAZNews ReleaseTransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
2024-06-10 07:00U:RNAZNews ReleaseNasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
2024-05-29 09:15U:RNAZNews ReleaseTransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
2024-05-13 08:30U:RNAZNews ReleaseTransCode Therapeutics Open Letter to Shareholders
2024-04-15 09:00U:RNAZNews ReleaseTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
2024-04-03 09:10U:RNAZNews ReleaseTransCode Therapeutics Reports 2023 Results; Provides Business Update
2024-03-28 08:30U:RNAZNews ReleaseTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
2024-03-11 09:00U:RNAZNews ReleaseTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
2024-03-06 16:15U:RNAZNews ReleaseTransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
2024-02-20 08:00U:RNAZNews ReleaseTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode ¢ € ™s RIG-I Agonist Immunotherapeutic
2024-01-31 16:05U:RNAZNews ReleaseNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders ¢ € ™ Equity Requirement and Continued Listing on The Nasdaq Stock Market
2024-01-29 08:30U:RNAZNews ReleaseTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
2024-01-22 16:45U:RNAZNews ReleaseTransCode Therapeutics Announces Closing of $7.25 Million Public Offering
2024-01-18 13:28U:RNAZNews ReleaseTransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
2024-01-12 16:05U:RNAZNews ReleaseTransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
2024-01-11 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces 1-for-40 Reverse Stock Split
2024-01-04 08:05U:RNAZNews ReleaseTransCode Therapeutics Publishes Open Letter Outlining Company ¢ € ™s Progress and Objectives
2023-12-12 08:30U:RNAZNews ReleaseTransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138